CereGate Secures Funding to Advance Closed-Loop Neurostimulation Platform for Movement Disorders
Summary
CereGate announced that it has secured additional funding to advance its closed-loop neurostimulation platform for treating movement disorders including Parkinson's disease and essential tremor. The company's technology uses real-time brain signal sensing to automatically adjust stimulation parameters for optimal therapeutic effect. The funding will support continued clinical development and regulatory activities.
Why it matters
Closed-loop neurostimulation represents the next frontier in neuromodulation therapy, potentially offering more consistent symptom control compared to traditional fixed-parameter stimulation. By automatically adjusting therapy based on real-time neural signals, the system could reduce side effects and extend battery life. This funding supports continued innovation in personalized neuromodulation approaches that could benefit the millions of patients with movement disorders worldwide.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial